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Objective: The potent physiologic endogenous angiogenic response to ischemic stimuli is often suboptimal, and therefore, a
better understanding of the basic mechanisms is essential for the use in therapeutic angiogenesis. Hypoxia-inducible factor-1
(HIF-1) is a major transcription factor that promotes ischemia-driven angiogenesis and is induced when the HIF-1 subunit
is upregulated. However, little is known about the endogenous angiogenic response and the role of HIF-1 in human critical
limb ischemia (CLI).We aimed to investigate the extent of the angiogenic response and the expression ofHIF-1 in the lower
limbs of CLI patients.
Method: Skeletalmuscle biopsy specimenswere obtained from the lower limbs of 12 patients withCLI and 12 patients without
limb ischemia (controls), with ethical committee approval. Microvessel density (MVD) was determined by using endothelial
marker anti-CD31, and HIF-1 expressions were determined by immunohistochemistry. MVD was measured as the median
number of microvessels in 200 magnification fields. Five random fields per section and three sections per biopsy specimen
were analyzed. Enzyme-linked immunoabsorbent assay and Western blotting were used to quantify the HIF-1 levels.
Colocalization between cell-specific antigens was investigated by double immunofluorescence labelling by using confocal
microscopy. Statistical analyses were performed with the Mann-Whitney U test.
Results: The CLI group have significantly higherMVD, with an increase of 2.7-fold compared with the controls (P< 0.001).
HIF-1 expression was significantly increased in CLI muscles (P < 0.001) and was localized to vascular endothelial cells.
Conclusions: Our findings suggest that the endogenous angiogenic response occurs in CLI. The increased HIF-1 level and
colocalization to vascular endothelial cells suggest thatHIF-1 plays a role in the physiologic endogenous angiogenic response
in CLI. Therefore, augmentation of the HIF-1 pathway may be an important aspect in therapeutic angiogenesis. (J Vasc
Surg 2006;43:125-33.)
Clinical Relevance: The results of clinical trials that have used therapy with a single proangiogenic factor have been
inconsistent and inconclusive. Becausemany of the angiogenic factors are regulated by hypoxia-inducible factor-1 (HIF-1),
induction of this transcription factor should theoretically provide a more physiologic mechanism of angiogenesis. This study
has demonstrated the physiologic angiogenic role of HIF-1 in human critical limb ischemia (CLI). With the encouraging
results of a gene therapy method using HIF-1 in preclinical models, therapeutic angiogenesis to augment HIF-1 pathway
in human CLI may represent a future promising treatment option for CLI.Critical limb ischemia (CLI) refers to a condition charac-
terized by chronic ischemic rest pain, ulcers, or gangrene
attributable to objectively proven arterial occlusive disease.
The incidence is approximately 500 to1000permillion a year,
with the highest rates among older subjects, individuals with a
history of smoking, and those with diabetes mellitus.1 Despite
recent advances in treatment, the rate of primary amputation
remains high, ranging from 10% to 40%,1 because the ana-
tomic extent and distribution of the disease in the peripheral
arteries makes them not amenable to conventional revascular-
ization techniques.
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doi:10.1016/j.jvs.2005.08.042In patients with CLI, arterial insufficiency results in
chronic muscle ischemia and hypoxia. Tissue hypoxia is a
strong physiologic stimulus for angiogenesis, a complex pro-
cess where both proangiogenic and antiangiogenic factors
interact with endothelial cells, smooth muscle cells, pericytes,
and the extracellular matrix in a highly regulated manner to
form new blood vessels from existing ones.2,3 Ischemia-in-
duced angiogenesis has been shown tooccur in animalmodels
of skeletal muscle ischemia.4-6 The administration of various
proangiogenic factors, for example, vascular endothelial
growth factor (VEGF) in animal models of hindlimb isch-
emia, had been shown to stimulate angiogenesis.7,8
Many of the proangiogenic and antiangiogenic factors are
directly or indirectly regulated by a master regulator of tissue
oxygen homeostasis, hypoxia-inducible factor-1 (HIF-1). 9 In
an in-vitro study using cultured human endothelial cells,
HIF-1 has been shown to induce several angiogenic factors,
including VEGF and angiopoietins, and promote endothe-
lial cell proliferation and tube formation.10
HIF-1, a heterodimeric transcription factor complex con-
sisting of HIF-1 and HIF-1 (also known as aryl hydrocar-
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nized as a DNA-binding factor that mediates hypoxia-
inducible activity of the erythropoietin 3= enhancer.11
Subsequent analysis identified HIF-1 as a phosphorylation-
dependent protein that binds the major groove of DNA
under hypoxic conditions.12
In normoxia, the HIF-1 subunit undergoes hydroxyla-
tion by prolyl hydroxylases that enables the binding of von
Hippel-Lindau protein. The resulting complex is then subject
to ubiquitination and proteasomal degradation,13-15 a process
that is inhibited under hypoxic conditions because the hy-
droxylation process is oxygen dependent.16 Another pro-
cess of hydroxylation by asparaginyl hydroxylase, also
known as factor-inhibiting HIF (FIH) inhibits the tran-
scriptional activity by blocking the interaction of HIF-1
with the transcriptional coactivator p300. In contrast, the
HIF-1 subunit is constitutively expressed in the nucleus of
cells. This suggests that stabilization of the HIF-1 subunit
is one mechanism for the induction of HIF-1 protein
expression and, consequently, HIF-1 activity. HIF-1 and
HIF-1 subunits are expressed in most human and animal
tissues.17-19 However, to our knowledge and after per-
forming a detailed search of PubMed and Medline (up to
the year 2005), we find that there has been no study on
HIF-1 activation in human skeletal muscle in CLI.
In view of the potential importance of ischemia-induced
angiogenesis in CLI, we therefore aimed to investigate the
extent of physiologic endogenous angiogenesis characterized
by microvessel densities in response to ischemia. Because
angiogenesis is dependent on HIF-1 activity, which requires
the stabilization and upregulation of the HIF-1 subunit
during hypoxia, we also investigated the HIF-1 expression
levels in the ischemic lower-limb skeletal muscles of patients
with CLI compared with controls without peripheral vascular
disease.
PATIENTS AND METHODS
Patients. Twelve patients each were recruited for the
CLI and control groups after approval from the local re-
search ethics committee. All patients agreed to participate
voluntarily and gave informed consent. There were 11 men
and 1 woman in each group. The mean age of the patients
with CLI was 70.09  5.74 years.
All 12 CLI patients presented with chronic CLI, as char-
acterized by rest pain of 2 weeks’ duration, with an ankle-
brachial pressure index (ABPI) of 0.3 and, in most of the
cases, tissue loss according to Fontaine classification stage III
and IV.20 All 12 CLI patients required lower-limb amputa-
tions. Seven patients underwent above-knee amputation, and
five patients underwent below-knee amputation, indicated for
chronic CLI. During surgery, a separate incision was per-
formed to obtain a gastrocnemius muscle biopsy specimen
before amputation.
In the control group, the mean age was 69.17  9.77
years. Peripheral vascular disease was excluded from the
controls by clinical history, examination, and ABPI mea-
surement (those with an ABPI of0.9 were excluded from
the control group). Gastrocnemius muscle specimens wereobtained from all patients in the beginning of saphenous
vein harvesting in coronary artery bypass graft operations.
Patient characteristics are summarized in Table 1.
Muscle biopsy specimens. Muscle biopsy specimens
were taken from the distal one third of gastrocnemius in all
cases of CLI and in the control group. The tissues were viable,
confirmedby the presence of nuclei in themyocytes and intact
morphology of skeletal musclemicroscopically. Areas of tissue
necrosis and surrounding inflammation were avoided in an
attempt to avoid the influences of these confounding factors.
To prevent HIF-1 degradation, the muscle samples
were snap frozen immediately within 10 to 15 seconds with
liquid nitrogen and stored at –80°C until further analysis
with enzyme-linked immunoabsorbent assay (ELISA) and
Western blotting. For immunohistochemistry and immu-
nofluorescence stainings, the muscle samples were fully
embedded in Tissue-Tek OCT compound (Bright Instru-
ment, Cambridgeshire, UK) on cork discs and frozen im-
mediately with liquid nitrogen. These were stored at –80°C
until cryosectioning.
Immnohistochemistry. Immunohistochemistry was
performedusing the avidin-biotin-complex (ABC) peroxidase
method. Serial frozen sections (6m)were cut at –25°C on a
cryostat and thaw mounted on slides coated with polylysine
(VWR International, Dorset, UK). The sections were then
air-dried, coded for blinded analysis, and stored at –80°C
before use. Sections were fixed in ice-cold acetone for 10
minutes, washed with phosphate-buffered saline (PBS), and
then nonspecific bindingwas blockedwith normal goat serum
(1:4 dilution) for 30minutes, followed by incubationwith the
primary antibodies anti-CD31 (1:100 dilution) (Dako,
Carpinteria, Calif) and anti-HIF-1 (1:500 dilution) (Novus
Biologicals, Littleton, Colo) for 1 hour at room temperature.
The sections were washed again with PBS before a 15-
minute immersion in 3% hydrogen peroxide in PBS in dark to
exhaust the endogenous peroxidase activity. After washing,
sections were incubated with biotinylated anti-mouse immu-
noglobulin G (IgG) secondary antibody (1:200 dilution)
(Vector Laboratories, Peterborough UK) diluted in PBS for
30 minutes, followed by incubation in avidin-biotinylated
horseradish peroxidase (HRP) complex (VectastainEliteABC
kit, Vector Laboratories) for 30 minutes. After washing, per-
oxidase activity was revealed using 3-amino-9-ethylcarbazole
Table I. Patient characteristics
Control (n  12) CLI (n  12)




Diabetes mellitus 6 7
Hypertension 4 6
Cigarette smoking 5 5
Hypercholesterolemia 8 9
Current statin therapy 8 7
Current aspirin therapy 10 11
CLI, Critical limb ischemia.(AEC).
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stained with Gill’s hematoxylin, washed in tap water, and
aqueously mounted with Crystal-Mount (Biomeda, Foster
City, Calif). Sections were viewed and photographed on a
Zeiss Axioskop 2mot plusmicroscope (Carl Zeiss,Göttingen,
Germany). Controls included an exchange of primary anti-
bodies with isotype matched control antibodies.
Quantification of microvessels. We used the method
employed by Paek et al21 with some modifications. Microves-
sels were quantified in a blinded fashion by counting the
number of CD31-positive microvessels within a 300- 
400-m grid at 200 magnification. Five random areas per
section and three sections per biopsy specimen (a total of 15
randomfields)were analyzed.Microvessel densitywas defined
as the number of microvessels per grid area (300 400 m).
Ratios ofmicrovessel tomuscle fiberwere calculatedby count-
ing microvessels in five random muscle fiber bundles per
section, with three sections (total of 15 random muscle fiber
bundles) per biopsy analyzed in blinded fashion at 200
magnification.
Double immunofluorescence labelling. To investi-
gate colocalization between cell-specific antigens, double im-
munofluorescence labelling was done. Cryosections (6-m
thick) were fixed in ice-cold acetone for 10 minutes, and
nonspecific binding was blocked in normal goat serum (1:4
dilution). After blocking, sections were incubated with the
first primary antibody (anti-HIF-1, diluted 1:500) for 1
hour, rinsed with PBS, and incubated with the appropriate
biotinylated secondary antibody for 30 minutes. Sections
were then rinsed with PBS and incubated with Avidin Texas
Red (25 g/mL) for 30 minutes. After further blocking
with normal goat serum (1:4 dilution), the sections were
then incubated with the second primary antibody (anti-
CD31, diluted 1:75) for 1 hour, rinsed with PBS, and
incubated with an appropriate secondary IgG fluorescein-
5-isothiocyanate (FITC) conjugate (12.5 g/ml) for 30
minutes. Sections were finally counterstained with 4,6-
diamidino-2-phenylindole (DAPI) to visualize cell nuclei.
The sections were then mounted using Gel-Mount anti-
fade medium (Biomeda). Sections were then viewed using
a Zeiss Axioskop 2 mot plus microscope with Axiovision
software. The controls included the exchange of each pri-
mary antibody with isotype-matched control antibodies.
Preparation of nuclear extracts. The chemicals and
reagents usedwere dithiothreitol (DTT), phenylmethyl sulfo-
nyl fluoride (PMSF), ethylenediaminetetraacetic acid
(EDTA), ethylene glycol bis(2-aminoethyl ether)-N,N,N=N=-
tetraacetic acid (EGTA), potassium chloride, and sodium
chloride. The method was adapted from previously published
methods22 with some modifications. All the steps were per-
formed on ice and centrifugation at 4°C. Protease inhibitor
cocktail tablet (Roche Diagnostics, Indianapolis, Ind), DTT,
and PMSF were added to all buffers just before use.
Between 100 and 500 mg of skeletal muscle frozen at
–80°C was cut into small pieces and suspended in ice-cold
buffer A (10 mM HEPES, pH7.9; 10 mM potassium chlo-
ride, 0.1 mM EDTA, 0.1 mM EGTA, 1 mMDTT, 0.5 mM
PMSF, and 1 protease inhibitor cocktail tablet to 10 mL ofsolution), which was added at the ratio of 2.5 times per gram
of tissue weight, with the minimum volume of 2 mL. These
were homogenized with power homogenizer Ultra-Turrax
T25 at 4°C and filtered through a nylon membrane. Ten
percent NP-40 was added at the ratio of 1:400 to the filtrated
volume, and the homogenates were further incubated at 4°C
for 10minutes to lyse the tissues, followedby centrifugation at
11,000 g for 1 minute at 4°C. The supernatant containing
mostly cytoplasmic constituents was removed and discarded.
Ice-cold buffer C (20 mM HEPES, pH7.9; 400 mM
sodium chloride; 1 mM each of DTT, EDTA, EGTA, and
PMSF; 1 protease inhibitor cocktail tablet to 5 mL of solu-
tion) was added to the nuclear pellet with the ratio of one
tenth of the original volume. The contents were thoroughly
mixed and put on a small rotary shaker for 15minutes at 4°C.
Finally, these were centrifuged again at 11,000g for 5 min-
utes. The supernatant containing the proteins from the nu-
clear extracts was removed carefully to a fresh tube. The
protein concentration was measured in the nuclear extract,
which was then aliquoted into several Eppendorf tubes and
stored at –80°C before use.
ELISA assay. ELISA assay was performed with the
ELISAkit (DuoSet IC,Human/MouseActiveHIF-1) from
R&D Systems, Oxon, UK. Capture antibody (4.0 g/mL in
PBS) was coated onto a 96-well plate with 100 L/well. The
plate was sealed and incubated overnight at room tempera-
ture. Each well was aspirated and washed with wash buffer
(PBS containing 0.05% Tween 20), and the process was
repeated two times. The plates were then blocked by adding
300L of reagent diluent (5% bovine serum albumin in wash
buffer) to each well and were incubated at room temperature
for 2 hours, followed by the aspiration/wash process as be-
fore. Biotin-labelled ds-DNA (3 L) was added to 50 g of
nuclear extract sample in anEppendorf tube. The final volume
was adjusted to 30 L with lysis buffer C and incubated at
room temperature for 30minutes. A blank containing biotin-
labelled ds oligonucleotide was also performed as a negative
control.
After 30minutes, 200Lof reagent diluent was added to
each sample and gently mixed, and a 100 L of sample was
placed in each well. The plate was sealed and left at room
temperature for incubation for 2 hours. The process of aspi-
ration/wash was repeated as before. Streptavidin-HRP (100
Lof the 1:60 dilution)was added to eachwell and incubated
for 20 minutes at room temperature in dark. The aspiration/
wash process was then repeated as before, but with a total
washing of 5 times. Substrate solution (100 L) (R&D Sys-
tems) was added to each well and incubated for 20minutes at
room temperature in dark. Finally, 50Lof stop solution (2N
sulfuric acid) was added to each well and tapped gently to
ensure thorough mixing. Optical density of each well was
determined immediately by using a microplate reader set to
450 nm and 550 nm. Optical imperfections in the plate were
corrected by subtracting the readings at 550 nm from the
readings at 450 nm.
Western blot analysis. Thenuclear extractsweremixed
with 4 loading buffer (20% sodiumdodecyl sulphate [SDS],
1M Tris hydrogen chloride, pH 6.8; -mercaptoethanol,
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January 2006128 Ho et alFig 1. Immunohistochemistry demonstrating CD31-positive microvessels.A, B,The CD31-positive microvessels are
visible as dark reddish brown against the background of hematoxylin counterstain. An example of a microvessel is
indicated by arrow i, and arrow ii indicates an example of a muscle nuclei. Increased immunopositive microvessels were
seen in the CLI group (B) compared with controls (A). Such sections were used for quantitative assessment of
microvessels and the microvessel-to-muscle fiber ratio (magnification, 200). C, Boxplot of microvessel density and
(D) microvessel-to-muscle fiber ratio. Boxes represent interquartile range, horizontal lines represent group medians,
and the whisker caps represent the 5th and 95th percentiles. Microvessel density was 2.7-fold higher in chronic critical
limb ischemia (CLI) muscle biopsy specimens than in controls (P  0.001, Mann-Whitney U test). The capillary-to-
muscle fiber ratio was also significantly higher in CLI compared to controls (P  0.001, Mann-Whitney U test).
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Volume 43, Number 1 Ho et al 129Fig 2. Immunohistochemistry demonstrating hypoxia-inducible factor-1 (HIF-1) expressions in (A) control and
(B) critical limb ischemia (CLI) muscles. There was an increased expression in the CLI muscles, demonstrated by the
increased immunoreactivity viewed as dark reddish brown (magnification 200). The HIF-1 levels were then
quantified using Western blotting and enzyme-linked immunoabsorbent assay (ELISA) assay. (C) Boxplot of ELISA
assay results of HIF-1 levels in the CLI and control biopsies specimens. Boxes represent interquartile range, horizontal
lines represent group medians, and the whisker caps represent the 5th and 95th percentiles. The CLI group has
significantly higher HIF-1 expression as represented by optical density (OD) compared with the control group (P 
0.001, Mann-WhitneyU test). (D)Western blot of HIF-1 in the control and CLI biopsy specimens. Stronger bands
were shown from the CLI biopsies (lanes 5 to 8) at the molecular weight of 120 kD, the molecular weight of HIF-1.
The bands were faintly detectable from biopsies from the control group (lanes 1 to 4).
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arated on 6% SDS-polyacrylamide gel (40 g of protein was
loaded per sample per well in a 10-well gel). SeeBlue Plus 2
prestained molecular weight markers (Invitrogen, Paisley,
UK) were used to determine the molecular weight of the
bands. The proteins were blotted onto Hybond-C Extra
nitrocellulose membranes (Amersham Biosciences, Bucks,
UK). After blotting, the membranes were blocked with 5%
drymilk in PBS containing 0.1% Tween 20 (PBS-T) for one
hour, and incubated overnight at 4°C with anti –HIF-1 at
1:500 dilution (Novus Biologicals) in 5% milk in PBS-T.
After 3 10-minute wash, the membranes were incubated
with HRP-conjugated goat antimouse IgG (H	L)
(Zymed, South San Francisco, Calif) diluted 1:2000 in 5%
milk for 45 minutes at room temperature. The membranes
were then washed 3 10 minutes before detection of
immunocomplex on the membrane with enhanced chemi-
luminescence (ECL) system (Amersham Biosciences), ac-
cording to manufacturer’s protocol.
Statistical analysis. Results are presented as median val-
ues with interquartile range. The two-tailed, non-parametric
Mann-WhitneyU test was performed by using SPSS statisti-
cal software (version 12.0) (SPSS, Chicago, Ill), with sta-
tistical significance inferred at P  0.05.
RESULTS
Immunohistochemistry
Identification of microvessels. Anti-CD31 antibody
(clone JC70) was used to identify the vascular endothelium.23
Microvessels appeared more abundant i n C L I (Fig 1, B)
biopsies compared with control muscles (Fig 1, A). These
appeared as dark reddish brown in the periphery of muscle
fibers, which were counterstained with hematoxylin and
appeared blue in color.
Microvessel density. The median number of CD31-
immunopositive microvessels per grid area was significantly
higher (2.7-fold) in ischemic muscle biopsy specimens,
with a median of 43.50 (30.25 to 59.25) microvessels per
grid, compared with controls at 16.50 (15.25 to 22.75)
(P  0.001) with 12 in each group (Fig 1, C). The ratio of
microvessel to muscle fiber was also significantly higher for
the CLI group, with the median of 2.20 (1.77 to 2.96)
compared with 1.31 (1.02 to 1.52) in the control group
(P  0.001) (Fig 1, D).
HIF-1. Immunohistochemical staining of tissues for
the levels of HIF-1 provides a guide to the activity of the
system because HIF-1 undergoes proteasomal degrada-
tion in the presence of oxygen. The CLI sections (Fig 2, B)
showed more immunoreactivity than the control muscle
(Fig 2, A). Serial 6-m cryosections of CLI biopsy speci-
mens stained with anti-CD31 (Fig 3, A) and anti-HIF-1
(Fig 3, B) antibodies demonstrated an almost identical
distribution pattern of immunoreactivity. This suggested a
very strong indication of colocalization between HIF-1
expression and vascular endothelium.
Double immunofluorescence labelling. Double im-
munofluorescence labelling on the CLI biopsy specimensconfirmed the colocalization between the HIF-1 expres-
sion and CD 31-positve vascular endothelium. The first
primary antibody, anti-HIF-1, was labelled with fluoro-
chrome Texas Red (red fluorescence) (Fig 3, C). The
second primary antibody, anti-CD31, was labelled with
fluorochrome FITC (green fluorescence) (Fig 3, D). There
was extensive colocalization between bothHIF-1 and CD
31, visualized as yellow fluorescence on the microvessels
(Fig 3, E). 
his showed the localization of HIF-1 and CD
31 in the same vascular endothelium.
ELISA assay. As indicated by immunohistochemistry,
there was an increased HIF-1 expression in the CLI group.
We therefore quantified the HIF-1 levels from the nuclear
extracts using ELISA assay (Fig 2, C). As indicated, the CLI
group had significantly higher HIF-1 levels, represented by
optical density (OD). The levels were 0.2673 (0.2380 to
0.3256) compared with controls at 0.1388 (0.1243 to
0.1631) (P 0.001), with 12 in each group.
Western blot analysis. The molecular weight of HIF-1
is 120 kD. Western blot analysis using nuclear extracts
confirmed the elevated HIF-1 levels indicated by immu-
nohistochemistry and shown in the ELISA assay. The CLI
group demonstrated strong HIF-1 bands at the region of
120 kD, and in the control group, there was lack of detectable
HIF-1 in the muscle biopsy specimens (Fig 2, D).
DISCUSSION
In this study, we have investigated the microvessel
density, ratio of microvessel to muscle fiber, HIF-1 levels
and colocalization of HIF-1 with vascular endothelium.
We used nuclear extract proteins for ELISA assay and
Western blot analysis because HIF-1 undergoes translo-
cation into cell nucleus and subsequent nuclear accumula-
tion during hypoxia.14 Furthermore, we were unable to
detect HIF-1 by Western blotting using skeletal muscle
homogenates alone (data is not shown).
Angiogenesis induced by ischemia has previously been
shown to occur in animal models of skeletal muscle isch-
emia4-6 and systemic hypoxia.24 In our study, we used criti-
cally ischemic human skeletal muscle to assess the physiologic
endogenous angiogenic response and found an increase
of microvessel density in the CLI muscles. We also
measured the ratio of microvessel to muscle fiber because
microvessel density may be influenced by the size and
number of muscle fibers. We also found a higher mi-
crovessel-to-muscle-fiber ratio in the CLI muscles.
In addition, we have also found an increased HIF-1
protein levels in CLI muscles. This is consistent with the
findings of raised VEGF level in human CLI skeletal muscles25
and with the view that VEGF is a well-known target gene for
HIF-1 and a key player in angiogenesis. Furthermore, our
study also supports a previous observation of increased activa-
tion of HIF-1 gene in human CLI muscles.26 Tuomisto et al
analyzed the gene expression of ischemic skeletalmuscles with
DNA array and found the upregulation of the HIF-VEGF-
VEGF receptor-2 pathway.26 However, the protein expressed
may be degraded at an equally high rate, resulting in no net
increase because the most important step in the regulation of
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Volume 43, Number 1 Ho et al 131Fig 3. Serial 6-m cryosections of critical limb ischemia muscle demonstrate the similar distribution pattern of
immunoreactivity between (A) CD31 and (B) HIF-1. This suggested a strong likelihood of colocalization between
the two antigens (magnification 400). The colocalization was further confirmed by using the double immunofluo-
rescence labelling technique, visualized on a representative single microvessel. (C)HIF-1was labelled with Texas Red
(red). (D) Vascular endothelium expressing CD31 antigen was labelled with fluorescein-5-isothiocyanate (FITC)
(green). (E) The colocalization of both HIF-1 and CD31-positive vascular endothelium on the same microvessel is
demonstrated by yellow color.
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bilization.16 Therefore, in this study, we measured the
HIF-1 protein levels in CLI muscles.
Although our results suggest that the process of angio-
genesis has occurred as a response to the ischemic condi-
tion, the question remains why, in most cases, the number
of new microvessels present does not appear to compensate
for the ischemia. Moreover, would augmentation of this
process by therapeutic angiogenesis be potentially useful?
Many animal models of limb ischemia that used various
proangiogenic factors in therapeutic angiogenesis showed
promising results in increasing capillary density, calf blood
pressure, muscle function, and muscle oxygen ten-
sion.7,8,27-30 Unfortunately, clinical trial results of the use of
therapeutic angiogenesis in CLI have not been conclu-
sive.31 The clinical trials used single-agent therapy, which
could explain the inconclusive results. Angiogenesis is a
multistep process that involves the interaction of multiple
proangiogenic and antiangiogenic factors with endothelial
cells, smooth muscle cells, pericytes, and extracellular ma-
trix.2,3 Studies have shown the synergistic effect and in-
creased vascular stability when more than one factor was
used in combination.32,33 Many of angiogenic factors,
including nitric oxide synthases, VEGF, VEGF receptor-2,
angiopoietin-2, platelet-derived growth factor, and
plasminogen-activator inhibitor are regulated by HIF-1.9 It is
plausible to suggest that by augmenting HIF-1, the angio-
genic response achieved is likely to have the interaction of a
combination of factors involved in angiogenesis instead of
the administration of a single growth factor.
Increasingly, more direct evidence on the angiogenic role
of HIF-1 in limb ischemia has become available. Milkiewicz
et al34 demonstrated that inhibition of endogenous HIF-1
inactivation induced angiogenesis in ischemic skeletal muscles
of mice. They inhibited the HIF-1 protein degradation by
using dimethyloxalylglycine, an inhibitor of the prolyl hydrox-
ylase enzymes that prompt the degradation ofHIF-1. Using
hybrid protein consisting of DNA-binding and dimerization
domains from the HIF-1 subunit and the transactivation
domain from herpes simplex virus VP16 protein, Vincent et
al35 showed that the HIF-1/VP16 hybrid transcription fac-
tor was able to promote significant improvement in the per-
fusion of rabbit ischemic hindlimb. These results confirm the
feasibility of such a novel approach for therapeutic angiogen-
esis in which neovascularizationmay be achieved indirectly by
use of a transcriptional regulatory strategy.
We have demonstrated the elevated levels of HIF-1 in
CLI muscles, and thus, the presence of HIF-1 may have a
physiologic effect in promoting angiogenesis in human CLI.
Thus, it is plausible to suggest that augmentation of HIF-1 in
harnessing the physiologic effect and mobilization of associ-
ated angiogenic growth factors may have a beneficial effect in
the treatment of CLI.
The colocalization of HIF-1 with vascular endothelium
suggests a possible role of HIF-1 on vascular endothelial
cells. It has been demonstrated that HIF-1 has a protective
property against hypoxia-induced apoptosis36 and may have
antiapoptotic action on vascular endothelium, apart frominducing the proangiogenic factors mentioned. Another study
on cultured human endothelial cells also strongly suggests a
potential antiapoptotic role for HIF-1 in hypoxic stress.37
The potential deleterious effects of modulating HIF-1
activity in human CLI are unknown. However, recent
studies have shown that harmful effects could accompany
therapeutic angiogenesis in relation to HIF-1 or VEGF,
especially through systemic administration in patients who
have known or yet unrecognized coexistent diseases such as
hemangioma formation, proliferative retinopathies, arthri-
tis, induction of occult tumor growth, or progression of
atherosclerotic plaques.38,39
CONCLUSION
Wehave demonstrated that in CLI skeletal muscles, there
is an increased microvessel densities and HIF-1 protein lev-
els. The HIF-1 colocalizes with CD 31-positive vascular
endothelium. Taken together, these data suggest the physi-
ologic endogenous angiogenic response involving HIF-1
is mounted in human CLI skeletal muscle. The potential
for augmenting this process for therapeutic benefit to in-
crease angiogenesis for those patients who are not amena-
ble for conventional revascularization techniques is not yet
realized. However, both therapeutic benefit and harmful
effects that may accompany HIF-1 modulation have to be
fully analyzed before they are used in humans.
We thank RK Walesby and C DiSalvo, Department of
Cardiothoracic Surgery,TheHeartHospital, London,UK for
their help in obtaining samples and Dorothy-Anne Sheriff for
her help in preparing the manuscript. We would also like to
thank Arthritis Research Campaign (ARC), UK in funding
the laboratory and the Rheumatology Department, The
Royal Free Hospital, London, UK.
AUTHOR CONTRIBUTIONS
Conception and design: TKH, VR, CMB, DJA, DMB
Analysis and interpretation: TKH, VR, MP, PL, CMB,
DJA, DMB
Data collection: TKH, MP, PL
Writing the article: TKH, VR, MP, PL, DJA, DMB
Critical revision of the article: CMB, DJA, DMB
Final approval of the article: TKH, VR, MP, PL, CMB,
DJA, DMB
Statistical analysis: TKH, VR
Obtained funding: DMB, DJA
Overall responsibility: DMB
REFERENCES
1. Novo S, Coppola G, Milio G. Critical limb ischemia: definition and
natural history. Curr Drug Targets Cardiovasc Haematol Disord 2004;
4:219-25.
2. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med
2000;6:389-95.
3. Carmeliet P. Angiogenesis in health and disease.NatMed 2003;9:653-60.
4. Hershey JC, Baskin EP, Glass JD, Hartman HA, Gilberto DB, Rogers
IT, et al. Revascularization in the rabbit hindlimb: dissociation between
capillary sprouting and arteriogenesis. Cardiovasc Res 2001;49:618-25.
JOURNAL OF VASCULAR SURGERY
Volume 43, Number 1 Ho et al 1335. Ito WD, Arras M, Scholz D, Winkler B, Htun P, Schaper W. Angiogen-
esis but not collateral growth is associated with ischemia after femoral
artery occlusion. Am J Physiol 1997;273:H1255-65.
6. Tang GL, Chang DS, Sarkar R, Wang R, Messina LM. The effect of
gradual or acute arterial occlusion on skeletal muscle blood flow,
arteriogenesis, and inflammation in rat hindlimb ischemia. J Vasc Surg
2005;41:312-20.
7. Mack CA, Magovern CJ, Budenbender KT, Patel SR, Schwarz EA,
Zanzonico P, et al. Salvage angiogenesis induced by adenovirus-
mediated gene transfer of vascular endothelial growth factor protects
against ischemic vascular occlusion. J Vasc Surg 1998;27:699-709.
8. ShimpoM, Ikeda U, Maeda Y, Takahashi M, Miyashita H, Mizukami
H, et al. AAV-mediated VEGF gene transfer into skeletal muscle
stimulates angiogenesis and improves blood flow in a rat hindlimb
ischemia model. Cardiovasc Res 2002;53:993-1001.
9. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of
the HIF system. Nat Med 2003;9:677-84.
10. Yamakawa M, Liu LX, Date T, Belanger AJ, Vincent KA, Akita GY,
et al. Hypoxia-inducible factor-1 mediates activation of cultured vascu-
lar endothelial cells by inducing multiple angiogenic factors. Circ Res
2003;93:664-73.
11. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de
novo protein synthesis binds to the human erythropoietin gene en-
hancer at a site required for transcriptional activation. Mol Cell Biol
1992;12:5447-54.
12. Wang GL, Semenza GL. Characterization of hypoxia-inducible factor 1
and regulation of DNA binding activity by hypoxia. J Biol Chem
1993;268:21513-8.
13. Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxia-inducible
factor 1alpha is mediated by an O2-dependent degradation domain via
the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1998;95:
7987-92.
14. Kallio PJ, WilsonWJ, O’Brien S, Makino Y, Poellinger L. Regulation of
the hypoxia-inducible transcription factor 1alpha by the ubiquitin-
proteasome pathway. J Biol Chem 1999;274:6519-25.
15. Salceda S, Caro J. Hypoxia-inducible factor 1alpha (HIF-1alpha) pro-
tein is rapidly degraded by the ubiquitin-proteasome system under
normoxic conditions. Its stabilization by hypoxia depends on redox-
induced changes. J Biol Chem 1997;272:22642-7.
16. Sutter CH, Laughner E, Semenza GL. Hypoxia-inducible factor 1alpha
protein expression is controlled by oxygen-regulated ubiquitination
that is disrupted by deletions and missense mutations. Proc Natl Acad
Sci USA 2000;97:4748-53.
17. Gradin K,McGuire J, Wenger RH, Kvietikova I, fhitelawML, Toftgard
R, et al. Functional interference between hypoxia and dioxin signal
transduction pathways: competition for recruitment of the Arnt tran-
scription factor. Mol Cell Biol 1996;16:5221-31.
18. Wenger RH, Rolfs A, Marti HH, Guenet JL, Gassmann M. Nucleotide
sequence, chromosomal assignment and mRNA expression of mouse
hypoxia-inducible factor-1 alpha. Biochem Biophys Res Commun
1996;223:54-9.
19. Wiener CM, Booth G, Semenza GL. In vivo expression of mRNAs
encoding hypoxia-inducible factor 1. Biochem Biophys Res Commun
1996;225:485-8.
20. Fontaine R, Kim M, Kieny R. Die Chirurgische Behandlung der Pe-
ripheren Dutch-Blutungsstorungen. Helv Chir Acta 1954;21.
21. Paek R, Chang DS, Brevetti LS, Rollins MD, Brady S, Ursell PC, et al.
Correlation of a simple direct measurement of muscle pO(2) to a clinical
ischemia index and histology in a rat model of chronic severe hindlimb
ischemia. J Vasc Surg 2002;36:172-9.
22. Lahiri DK, Ge Y. Electrophoretic mobility shift assay for the detection
of specific DNA-protein complex in nuclear extracts from the cultured
cells and frozen autopsy human brain tissue. Brain Res Brain Res Protoc
2000;5:257-65.23. Parums DV, Cordell JL, Micklem K, Heryet AR, Gatter KC, Mason
DY. JC70: a new monoclonal antibody that detects vascular endothe-
lium associated antigen on routinely processed tissue sections. J Clin
Pathol 1990;43:752-7.
24. Deveci D, Marshall JM, Egginton S. Chronic hypoxia induces pro-
longed angiogenesis in skeletal muscles of rat. Exp Physiol 2002;87:
287-91.
25. Choksy S, Pockley AG, Wajeh YE, Chan P. VEGF and VEGF receptor
expression in human chronic critical limb ischaemia. Eur J Vasc Endo-
vasc Surg 2004;28:660-9.
26. Tuomisto TT, Rissanen TT, Vajanto I, Korkeela A, Rutanen J, Yla-
Herttuala S. HIF-VEGF-VEGFR-2, TNF-alpha and IGF pathways are
upregulated in critical human skeletal muscle ischemia as studied with
DNA array. Atherosclerosis 2004;174:111-20.
27. Chang DS, Su H, Tang GL, Brevetti LS, Sarkar R, Wang R, et al.
Adeno-associated viral vector-mediated gene transfer of VEGF normal-
izes skeletal muscle oxygen tension and induces arteriogenesis in isch-
emic rat hindlimb. Mol Ther 2003;7:44-51.
28. Lee SL, Pevec WC, Carlsen RC. Functional outcome of new blood
vessel growth into ischemic skeletal muscle. J Vasc Surg 2001;34:1096-
102.
29. Walder CE, Errett CJ, Bunting S, Lindquist P, Ogez JR,HeinsohnHG,
et al. Vascular endothelial growth factor augments muscle blood flow
and function in a rabbit model of chronic hindlimb ischemia. J Cardio-
vasc Pharmacol 1996;27:91-8.
30. Wright CE. Effects of vascular endothelial growth factor (VEGF)A
and VEGFB gene transfer on vascular reserve in a conscious rabbit
hindlimb ischaemia model. Clin Exp Pharmacol Physiol 2002;29:
1035-9.
31. Collinson DJ, Donnelly R. Therapeutic angiogenesis in peripheral
arterial disease: can biotechnology produce an effective collateral circu-
lation? Eur J Vasc Endovasc Surg 2004;28:9-23.
32. Asahara T, Bauters C, Zheng LP, Takeshita S, Bunting S, Ferrara N,
et al. Synergistic effect of vascular endothelial growth factor and
basic fibroblast growth factor on angiogenesis in vivo. Circulation
1995;92:II365-71.
33. Cao R, Brakenhielm E, Pawliuk R, Wariaro D, Post MJ, Wahlberg E,
et al. Angiogenic synergism, vascular stability and improvement of
hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat
Med 2003;9:604-13.
34. Milkiewicz M, Pugh CW, Egginton S. Inhibition of endogenous HIF
inactivation induces angiogenesis in ischaemic skeletal muscles of mice.
J Physiol 2004;560:21-6.
35. Vincent KA, Shyu KG, Luo Y, Magner M, Tio RA, Jiang C, et al.
Angiogenesis is induced in a rabbit model of hindlimb ischemia by
naked DNA encoding an HIF-1alpha/VP16 hybrid transcription fac-
tor. Circulation 2000;102:2255-61.
36. Akakura N, Kobayashi M, Horiuchi I, Suzuki A, Wang J, Chen J, et al.
Constitutive expression of hypoxia-inducible factor-1alpha renders pan-
creatic cancer cells resistant to apoptosis induced by hypoxia and nutri-
ent deprivation. Cancer Res 2001;61:6548-54.
37. Yu EZ, Li YY, Liu XH, Kagan E, McCarron RM. Antiapoptotic action
of hypoxia-inducible factor-1 alpha in human endothelial cells. Lab
Invest 2004;84:553-61.
38. Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake
MD. Vascular endothelial growth factor enhances atherosclerotic
plaque progression. Nat Med 2001;7:425-9.
39. Epstein SE, Kornowski R, Fuchs S, Dvorak HF. Angiogenesis therapy:
amidst the hype, the neglected potential for serious side effects. Circu-
lation 2001;104:115-9.Submitted Jun 16, 2005; accepted Aug 19, 2005.
